It is not clear that HDAC inhibitors can induce a sufficient level HIV-1 expression in vivo to allow clearance of latent infection, and so combinatorial approaches to disrupt latency have been proposed [18], [19]. The gene discussed is HDAC9; the disease is disease arising from reactivation of latent virus.